SCHEMBL2426673

SCHEMBL2426673

OC(CCc1ccccc1)c1c(Cl)ccc(F)c1Cl

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 2/20 0.38
PPARA Q07869 2/20 0.38
IDO1 P14902 1/20 0.37
TDO2 P48775 1/20 0.37
KMT2A Q03164 2/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
CYP2C19 P33261 1/20 0.37
POLB P06746 1/20 0.36
MAPK14 Q16539 1/20 0.35
MEN1 O00255 1/20 0.34
GAA P10253 1/20 0.34
ATM Q13315 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
MET P08581 1/20 0.34
METAP2 P50579 1/20 0.34
ANPEP P15144 2/20 0.34
ERAP1 Q9NZ08 2/20 0.34
ERAP2 Q6P179 1/20 0.34
MMP7 P09237 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2422975 0.78 MET (0.36) MET
SCHEMBL2420459 0.74 MET (0.38) MET
SCHEMBL2422450 0.71 MET (0.39) MET
SCHEMBL3070798 0.70 PPARG (0.50) PPARGPPARAKMT2ANPC1RAB9A
SCHEMBL30849674 0.70 IDO1 (0.58) IDO1TDO2CYP2C19POLBMAPK14
SCHEMBL30849665 0.70 PPARG (0.50) PPARGPPARAKMT2ANPC1RAB9A
SCHEMBL2422805 0.70 MET (0.33) ATML3MBTL1MET
SCHEMBL2425337 0.70 MET (0.33) MET
SCHEMBL1581742 0.69 MET (0.44) MET
SCHEMBL30005568 0.69 MET (0.44) MET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2265616-B1 FURO-AND THIENO[3,2-C]PYRIDINES OSI PHARM INC (US) 2013-11-20 EP disclosed
US-8022206-B2 Furo[3,2-C]pyridines OSI Pharmaceuticals, LLC (US) 2011-09-20 US disclosed
US-8022206-B2 Furo[3,2-C]pyridines OSI Pharmaceuticals, LLC (US) 2011-09-20 US disclosed
US-8022206-B2 Furo[3,2-C]pyridines OSI Pharmaceuticals, LLC (US) 2011-09-20 US disclosed
EP-2265616-A1 FURO-AND THIENO[3,2-C]PYRIDINES OSI Pharmaceuticals, Inc. (US) 2010-12-29 EP disclosed
WO-2009100282-A1 FURO-AND THIENO[3,2-C] PYRIDINES OSI PHARMACEUTICALS, INC. (US) 2009-08-13 WO disclosed
US-20090197864-A1 Furo- and Thieno [3,2-c] Pyridines OSI PHARMACEUTICALS, INC. 2009-08-06 US disclosed
US-20090197864-A1 Furo- and Thieno [3,2-c] Pyridines OSI PHARMACEUTICALS, INC. 2009-08-06 US disclosed
US-20090197864-A1 Furo- and Thieno [3,2-c] Pyridines OSI PHARMACEUTICALS, INC. 2009-08-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090197864-A1 Furo- and Thieno [3,2-c] Pyridines RET, MET, ERBB2 PPARG 1266/4885PPARA 1987/4885IDO1 3179/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.